Developing novel therapies for life-threatening acute respiratory and critical care conditions.
Impact of Acute Respiratory Depression
Development of Novel Compounds
Our lead drug candidate, ENA-001, is a patent-protected new chemical entity (NCE) beginning additional clinical trials in the fourth quarter of 2021. With its novel mechanism-of-action and demonstrated safety and efficacy, it holds the potential to dramatically improve the lives of those impacted by several of the Nation’s Top Health Emergencies; including the Drug Overdose Epidemic and apnea of prematurity. ENA-001 will offer new treatment options for physicians, emergency responders, and care-givers addressing respiratory depression in multiple settings.
Who We Are
The Enalare Therapeutics team includes a very experienced management team, Board of Directors, world-renowned scientific advisors, and talented team members that are determined to advance our mission. This team brings decades of experience with top-tier biopharma companies, proven ability to develop and launch innovative products, and a track record of consistently creating significant shareholder value.